Search Results - "Mileshkin L"

Author Listing.

Source: Asia Pacific Journal of Clinical Oncology. 2024 Suppl 3, Vol. 20, p272-285. 14p.

Author List.

Source: Asia Pacific Journal of Clinical Oncology. 2024 Suppl 2, Vol. 20, p65-68. 4p.

Author Listing.

Source: Asia Pacific Journal of Clinical Oncology. 2022Supplement, Vol. 18, p237-248. 12p.

AUTHOR INDEX.

Source: Asia Pacific Journal of Clinical Oncology. Nov2021 Supplement S9, Vol. 17, p209-218. 10p.

Author Listing.

Source: Asia Pacific Journal of Clinical Oncology. Nov2023 Supplement 1, Vol. 19, p275-289. 15p.

Indianapolis Consensus Recommendations for Promoting Diversity and Equity in Cancer Clinical Trials: "The Indianapolis Black Paper".

Authors: Birhiray, Maya N. Hantel, Andrew Mikhael, Joseph R. et al.

Source: Diversity & Inclusion Research. Jul2026, Vol. 3 Issue 3, p1-11. 11p.

Mesonephric‐Like Adenocarcinoma of the Endometrium and the Impact of the Updated 2023 FIGO Staging System.

Authors: Ogunmuyiwa, Joy Hamilton, Alexandra Hayek, Judy et al.

Source: Case Reports in Obstetrics & Gynecology. 5/9/2026, Vol. 2026, p1-5. 5p.

Author Listing.

Source: Asia Pacific Journal of Clinical Oncology. Nov2020 Supplement S8, Vol. 16, p208-218. 11p.

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.

Authors: Burdett, Nikki L. Willis, Madelynne O. Pandey, Ahwan et al.

Source: Scientific Reports. 12/11/2023, Vol. 13 Issue 1, p1-10. 10p.

Author Index.

Source: Asia Pacific Journal of Clinical Oncology. Nov2019 Supplement S9, Vol. 15, p213-223. 11p.

Author Index.

Source: Asia Pacific Journal of Clinical Oncology. Aug2019 Supplement S5, Vol. 15, p101-104. 4p.

Author index.

Source: Asia Pacific Journal of Clinical Oncology. Nov2023 Supplement 1, Vol. 19, p62-64. 3p.

The Swaying Pendulum: Factors Influencing Physical Activity Participation in Women With Recurrent Ovarian Cancer.

Authors: Gildea, Gabrielle C. Spence, Rosalind R. Jones, Tamara L et al.

Source: Journal of Physical Activity & Health. May2025, Vol. 22 Issue 5, p590-598.

Author Index.

Source: Asia Pacific Journal of Clinical Oncology. Aug2020 Supplement S2, Vol. 16, p48-50. 3p.

Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting.

Authors: Madariaga A Veneziani A Bookman M et al.

Source: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2026 Jun 23; Vol. 36 (9), pp. 104827. Date of Electronic Publication: 2026 Jun 23.

Publication Type: Journal Article; Review

Journal Info: Publisher: BMJ Country of Publication: United States NLM ID: 9111626 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE

Unravelling mutational signatures with plasma circulating tumour DNA.

Authors: Hollizeck S Wang N Wong SQ et al.

Source: Nature communications [Nat Commun] 2024 Nov 14; Vol. 15 (1), pp. 9876. Date of Electronic Publication: 2024 Nov 14.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer—A Single-Center Retrospective Study.

Authors: Miedziarek, Cezary Bochyński, Hubert Bociańska, Katarzyna et al.

Source: Cancers. Nov2025, Vol. 17 Issue 22, p3605. 12p.

Feasibility of TP53 -Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS.

Authors: Marlin, Regine Jean-Laurent, Mehdi Joachim, Clarisse et al.

Source: Cancers. Apr2026, Vol. 18 Issue 7, p1102. 12p.

Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary.

Authors: Rebello RJ Posner A Dong R et al.

Source: Nature communications [Nat Commun] 2025 May 20; Vol. 16 (1), pp. 4422. Date of Electronic Publication: 2025 May 20.

Publication Type: Journal Article

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Authors: Lorusso D Gladieff L O'Malley DM et al.

Source: Lancet (London, England) [Lancet] 2026 Apr 18; Vol. 407 (10538), pp. 1513-1524. Date of Electronic Publication: 2026 Apr 10.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE